Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.15
IRWD's Cash to Debt is ranked lower than
61% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. IRWD: 1.15 )
Ranked among companies with meaningful Cash to Debt only.
IRWD' s Cash to Debt Range Over the Past 10 Years
Min: 1.1  Med: 42.32 Max: 420.39
Current: 1.15
1.1
420.39
Equity to Asset 0.15
IRWD's Equity to Asset is ranked lower than
95% of the 701 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. IRWD: 0.15 )
Ranked among companies with meaningful Equity to Asset only.
IRWD' s Equity to Asset Range Over the Past 10 Years
Min: -1.86  Med: 0.15 Max: 0.63
Current: 0.15
-1.86
0.63
F-Score: 5
Z-Score: -0.33
M-Score: 134.21
WACC vs ROIC
8.87%
-397.81%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -68.26
IRWD's Operating margin (%) is ranked lower than
88% of the 708 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.77 vs. IRWD: -68.26 )
Ranked among companies with meaningful Operating margin (%) only.
IRWD' s Operating margin (%) Range Over the Past 10 Years
Min: -1101.36  Med: -204.91 Max: -48.43
Current: -68.26
-1101.36
-48.43
Net-margin (%) -95.40
IRWD's Net-margin (%) is ranked lower than
89% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.28 vs. IRWD: -95.40 )
Ranked among companies with meaningful Net-margin (%) only.
IRWD' s Net-margin (%) Range Over the Past 10 Years
Min: -1192.31  Med: -197.18 Max: -48.34
Current: -95.4
-1192.31
-48.34
ROE (%) -144.82
IRWD's ROE (%) is ranked lower than
96% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.97 vs. IRWD: -144.82 )
Ranked among companies with meaningful ROE (%) only.
IRWD' s ROE (%) Range Over the Past 10 Years
Min: -299.34  Med: -155.35 Max: -48.14
Current: -144.82
-299.34
-48.14
ROA (%) -28.29
IRWD's ROA (%) is ranked lower than
85% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. IRWD: -28.29 )
Ranked among companies with meaningful ROA (%) only.
IRWD' s ROA (%) Range Over the Past 10 Years
Min: -107.22  Med: -36.19 Max: -22.85
Current: -28.29
-107.22
-22.85
ROC (Joel Greenblatt) (%) -395.37
IRWD's ROC (Joel Greenblatt) (%) is ranked lower than
87% of the 757 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.44 vs. IRWD: -395.37 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
IRWD' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -672.27  Med: -335.33 Max: -190.56
Current: -395.37
-672.27
-190.56
Revenue Growth (3Y)(%) -9.30
IRWD's Revenue Growth (3Y)(%) is ranked lower than
82% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. IRWD: -9.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
IRWD' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -30.35 Max: -5.4
Current: -9.3
EBITDA Growth (3Y)(%) 6.90
IRWD's EBITDA Growth (3Y)(%) is ranked lower than
53% of the 545 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. IRWD: 6.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
IRWD' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -25.65 Max: 51.9
Current: 6.9
0
51.9
EPS Growth (3Y)(%) 13.70
IRWD's EPS Growth (3Y)(%) is ranked higher than
61% of the 501 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. IRWD: 13.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
IRWD' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -21.35 Max: 54.2
Current: 13.7
0
54.2
» IRWD's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2015

IRWD Guru Trades in Q2 2015

Jim Simons 69,303 sh (New)
Steven Cohen 1,378,600 sh (+83.81%)
Vanguard Health Care Fund 4,367,387 sh (+3.21%)
» More
Q3 2015

IRWD Guru Trades in Q3 2015

Paul Tudor Jones 12,514 sh (New)
Steven Cohen 1,612,400 sh (+16.96%)
Vanguard Health Care Fund 4,367,387 sh (unchged)
Jim Simons 31,253 sh (-54.90%)
» More
Q4 2015

IRWD Guru Trades in Q4 2015

Jim Simons 242,553 sh (+676.10%)
Paul Tudor Jones 26,514 sh (+111.87%)
Vanguard Health Care Fund 4,367,387 sh (unchged)
Samuel Isaly 1,237,800 sh (unchged)
Steven Cohen 1,537,900 sh (-4.62%)
» More
Q1 2016

IRWD Guru Trades in Q1 2016

Ken Fisher 235,675 sh (New)
Samuel Isaly 1,237,800 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with IRWD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 15.74
IRWD's P/B is ranked lower than
96% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. IRWD: 15.74 )
Ranked among companies with meaningful P/B only.
IRWD' s P/B Range Over the Past 10 Years
Min: 5.45  Med: 11.13 Max: 47.65
Current: 15.74
5.45
47.65
P/S 9.92
IRWD's P/S is ranked lower than
83% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. IRWD: 9.92 )
Ranked among companies with meaningful P/S only.
IRWD' s P/S Range Over the Past 10 Years
Min: 2.63  Med: 19.17 Max: 75.43
Current: 9.92
2.63
75.43
Current Ratio 6.54
IRWD's Current Ratio is ranked higher than
84% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. IRWD: 6.54 )
Ranked among companies with meaningful Current Ratio only.
IRWD' s Current Ratio Range Over the Past 10 Years
Min: 2.33  Med: 3.98 Max: 6.54
Current: 6.54
2.33
6.54
Quick Ratio 6.54
IRWD's Quick Ratio is ranked higher than
86% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. IRWD: 6.54 )
Ranked among companies with meaningful Quick Ratio only.
IRWD' s Quick Ratio Range Over the Past 10 Years
Min: 2.33  Med: 3.98 Max: 6.54
Current: 6.54
2.33
6.54
Days Inventory 64.93
IRWD's Days Inventory is ranked higher than
78% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.30 vs. IRWD: 64.93 )
Ranked among companies with meaningful Days Inventory only.
IRWD' s Days Inventory Range Over the Past 10 Years
Min: 51.22  Med: 462.06 Max: 1266.91
Current: 64.93
51.22
1266.91
Days Sales Outstanding 7.04
IRWD's Days Sales Outstanding is ranked higher than
96% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.16 vs. IRWD: 7.04 )
Ranked among companies with meaningful Days Sales Outstanding only.
IRWD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.05  Med: 8.18 Max: 889.76
Current: 7.04
0.05
889.76
Days Payable 121.47
IRWD's Days Payable is ranked higher than
74% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.22 vs. IRWD: 121.47 )
Ranked among companies with meaningful Days Payable only.
IRWD' s Days Payable Range Over the Past 10 Years
Min: 139.16  Med: 345.67 Max: 8217.61
Current: 121.47
139.16
8217.61

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 15.74
IRWD's Price/Tangible Book is ranked lower than
93% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. IRWD: 15.74 )
Ranked among companies with meaningful Price/Tangible Book only.
IRWD' s Price/Tangible Book Range Over the Past 10 Years
Min: 6.43  Med: 14.21 Max: 36.86
Current: 15.74
6.43
36.86
Price/Median PS Value 0.51
IRWD's Price/Median PS Value is ranked higher than
90% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. IRWD: 0.51 )
Ranked among companies with meaningful Price/Median PS Value only.
IRWD' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.43  Med: 1.00 Max: 3.03
Current: 0.51
0.43
3.03
Earnings Yield (Greenblatt) (%) -7.80
IRWD's Earnings Yield (Greenblatt) (%) is ranked lower than
84% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. IRWD: -7.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IRWD' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -13.59  Med: 0.00 Max: 0
Current: -7.8
-13.59
0

More Statistics

Revenue(Mil) $150
EPS $ -1.01
Beta0.88
Short Percentage of Float23.25%
52-Week Range $7.35 - 14.60
Shares Outstanding(Mil)143.39

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 225 319 402
EPS($) -0.66 -0.24 0.35
EPS without NRI($) -0.66 -0.24 0.35

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TSE:8129, SZSE:002737, SZSE:000650, NAS:RDUS, TSE:4569 » details
Traded in other countries:I76.Germany,
Ironwood Pharmaceuticals Inc was incorporated in Delaware on January 5, 1998. On April 7, 2008, the Company changed its name from Microbia, Inc. to Ironwood Pharmaceuticals, Inc. The Company is an entrepreneurial pharmaceutical company that discovers, develops and intends to commercialize differentiated medicines that improve patients' lives. The Company currently operates its human therapeutics business segment. Human therapeutics segment consists of the development and commercialization of its product candidates, including linaclotide. The Company is subject to federal, state, city and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials.
» More Articles for IRWD

Headlines

Articles On GuruFocus.com
A Look at Steven Cohen's Investment in Ironwood Pharmaceuticals Aug 25 2015 
Weekly 3-Year Low Highlight: EXC, RVBD, IRWD, SHOS Oct 27 2013 
Five-Year Lows: Singapore Airlines Limited, Gold Field Ltd., Ironwood Pharmaceuticals Inc., Northwes Oct 22 2013 
Weekly CEO Buys Highlight: GDOT, VOCS, PES, IRWD, ABR Nov 11 2012 
Edward Owens Made Few Purchases In Times of Changes: Boston Scientific Corp., Ironwood Pharmaceutica May 10 2010 
Vanguard Health Care Fund Buys Ironwood Pharmaceuticals Inc., Johnson & Johnson, Boston Scientific C May 06 2010 

More From Other Websites
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Ironwood... Apr 28 2016
ETF’s with exposure to Ironwood Pharmaceuticals, Inc. : April 28, 2016 Apr 28 2016
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ironwood... Apr 28 2016
IMPORTANT SHAREHOLDER NOTICE: Goldberg Law PC Announces an Investigation of Claims against Ironwood... Apr 27 2016
INVESTOR ALERT: Investigation of Ironwood Pharmaceuticals, Inc. Announced by Law Offices of Howard... Apr 27 2016
Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IRWD-US :... Apr 27 2016
What’s the Deal With These 5 Tanking Stocks? Apr 26 2016
Ironwood Pharmaceuticals Investigated for Potential Violations of Federal Securities Laws by Block &... Apr 26 2016
BUZZ-Ironwood Pharma plunges after Phase Five report Apr 26 2016
​Ironwood to pay up to $256M plus royalties for U.S. rights to gout drug Apr 26 2016
IRONWOOD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Apr 26 2016
AstraZeneca sells U.S. gout drug rights to Ironwood for up to $265 million Apr 26 2016
Ironwood Pharmaceuticals Enters into U.S. Licensing Agreement with AstraZeneca for Lesinurad Apr 26 2016
Ironwood Pharmaceuticals Enters into U.S. Licensing Agreement with AstraZeneca for Lesinurad Apr 26 2016
Ironwood Pharmaceuticals to Host First Quarter 2016 Investor Update Call Apr 25 2016
Ironwood Pharmaceuticals to Host First Quarter 2016 Investor Update Call Apr 25 2016
Ironwood to decide soon on a target disease for its next potential blockbuster Apr 25 2016
Be Wary of These Five Tanking Stocks Today, Office Depot Among Them Apr 20 2016
IRONWOOD PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers,... Apr 07 2016
Ironwood Pharmaceuticals Appoints Andrew Dreyfus to Board of Directors Apr 07 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK